Coronavirus vaccine

Novavax Is Oversold, Time To Buy for Future Growth

By Faisal Humayun, InvestorPlace Contributor
NVAX stock seems oversold. Focus on low-income countries is likely to deliver revenue and cash flows from covid-19 vaccine sales in 2022.

Blockchain: How This Next Great Tech Platform Could Help Fight COVID-19

By InvestorPlace Research Staff
Simply put, blockchain is the safest way to store and transfer information ever created, which makes it ideal for tracking vaccines.

Be Careful with Novavax and the Recent Surge in NVAX Stock

By Luke Lango, InvestorPlace Senior Investment Analyst
Covid-19 vaccine stocks are on fire, but many of them appear to be out over their skis, including the group's hottest name, NVAX stock.

7 Red-Hot Vaccine Stocks Racing to Develop a Coronavirus Cure

By Luke Lango, InvestorPlace Senior Investment Analyst
A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.

There’s Little Reason to Hold Onto iBio Stock as it Chases Latest Virus

By Ian Bezek, InvestorPlace Contributor
Traders have bought up a bunch of different biotech stocks as potential coronavirus cures. iBio is one that you should get rid of while it's still up.

Bullish Play on Inovio as it Develops COVID-19 Vaccine

By Ken Trester
The major indexes continue to rally. Take advantage by using a bullish position on Inovio Pharmaceuticals, Inc. (NASDAQ:INO).